ADVB — what changed in the latest 10-Q
A section-by-section comparison of ADVB's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-05-15 vs the prior 10-Q · 2026-02-13
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +27 | −23 | ~16 | 47 |
| Market risk (Item 3) | Text added/removed | 0 | 0 | ~1 | 3 |
| Controls & procedures | Text added/removed | 0 | 0 | ~1 | 0 |
| Legal proceedings | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Other information | Text added/removed | 0 | 0 | ~1 | 0 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Risk factors
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-05-15
Subsequent to the quarter ended March 31, 2026, as part of our ongoing strategic efforts to realign our business operations, the Company entered into a Share Purchase Agreement on April 2, 2026, to acquire 100% of the equity interest in Acellent Technologies (Hong Kong) Co. Limited. This acquisition…
In addition to these strategic developments, the Company secured further liquidity to support its transition and general working capital needs. On April 13, 2026, the Company entered into an unsecured short-term loan agreement with an individual, Jie Wang, for a principal amount of $600,000. This lo…
For the nine-month periods ended March 31, 2026 and 2025, the Company conducted its business through Advanced Biomed Taiwan as research and development centers for technology research and product development.
Comparison of Results of Operations for the Three-Month Periods Ended March 31, 2026 and 2025
Comparison of Results of Operations for the Nine-Month periods ended March 31, 2026 and 2025
Text removed vs the prior filing · source: 10-Q · 2026-02-13
For the six-month periods ended December31, 2025 and 2024, the Company conducted its business through Advanced Biomed Taiwan as research and development centers for technology research and product development.
Comparison of Results of Operations for the Three-Month Periods Ended December 31, 2025 and 2024
Comparison of Results of Operations for the Six-Month Periods Ended December 31, 2025 and 2024
Since our inception, we do not have any products approved for sale, we have not generated any revenue from the sale of products, and we do not expect to generate revenue from the sale of our product candidates until we complete clinical development, submit regulatory filings and receive approvals fr…
For the three-month periods ended December 31, 2025 and 2024, our general and administrative expenses amounted to $0.2 million, $0.07 million, respectively. The increase in administrative expenses by approximately $0.14 million or 211% for the three-month period ended December 31, 2025, is mainly at…
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice